Patents by Inventor Sara Petersen Bjorn
Sara Petersen Bjorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8058008Abstract: Cells are genetically modified to express a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence.Type: GrantFiled: February 5, 2002Date of Patent: November 15, 2011Assignee: Fisher Bioimage APSInventors: Ole Thastrup, Sara Petersen Bjørn, Soren Tullin, Kasper Almholt, Kurt Scudder
-
Publication number: 20090023598Abstract: A method for screening a library of compounds to detect a biologically active compound that modulates intracellular translocation of a subunit of a component of an intracellular pathway affecting intracellular processes includes: culturing one or more cells containing a nucleotide sequence coding for a hybrid polypeptide comprising a luminophore linked to the subunit of the component; introducing a compound of the library of compounds into the cell culture; screening the compound to determine whether the compound modulates the intracellular translocation of the subunit of the component; measuring light emitted from the luminophore to determine a first distribution; measuring light emitted from the luminophore to determine a second distribution; computing a variation between the first distribution and the second distribution by processing the measured light, any variation is indicative that the compound is biologically active. The method is also performed with a library of compounds.Type: ApplicationFiled: October 29, 2007Publication date: January 22, 2009Applicant: FISHER BIOIMAGE APSInventors: Ole Thastrup, Sara Petersen Bjorn, Soren Tullin, Kasper Almholt, Kurt Scudder
-
Patent number: 7476518Abstract: A GFP with an F64L mutation and E222G mutation is provided. This GFP has a bigger Stokes shift compared to other GFPs making it very suitable for high throughput screening due to a better resolution. This GFP also has an excitation maximum between the yellow GFP and the cyan GFP allowing for clearer band separation when used together with those GFPs. Examples include the sequences in SEQ ID NOs: 3 and 4.Type: GrantFiled: August 19, 2005Date of Patent: January 13, 2009Assignee: Fisher BioImage APSInventors: Sara Petersen Bjørn, Len Pagliaro, Ole Thastrup
-
Patent number: 7314915Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.Type: GrantFiled: September 23, 2004Date of Patent: January 1, 2008Assignee: Fisher BioImage APSInventors: Ole Thastrup, Søren Tullin, Lars Kongsbak Poulsen, Sara Petersen Bjørn
-
Patent number: 7282347Abstract: A method is described to assay for protein interactions in living cells, e.g. by the introduction of two heterologous conjugates into the cell. The method uses the measurement of cellular distribution of a detectable component (e.g. a GFP-labeled˜fluorescent probe) to indicate the presence or absence of an interaction between that component and a second component of interest. The method uses the knowledge that certain components can be stimulated to redistribute within the cell to defined locations. Inducible redistribution systems make it possible to determine if specific interactions occur between components. Inducible systems are described where it is demonstrated that the redistribution stimuli are essentially “null”, in that they affect no other system in the cell during the assay period, other than the component whose redistribution can be induced.Type: GrantFiled: July 3, 2001Date of Patent: October 16, 2007Assignee: Fisher Bioimage APSInventors: Sara Petersen Bjorn, Ole Thastrup, Bernard Robert Terry, Grith Hagel, Soren Jensby Nielsen
-
Patent number: 7001986Abstract: A GFP with an F64L mutation and an E222G mutation is provided. This GFP has a bigger Stokes shift compared to other GFPs making it very suitable for high throughput screening due to a better resolution. This GFP also has an excitation maximum between the yellow GFP and the cyan GFP allowing for cleaner band separation when used together with those GFPs.Type: GrantFiled: June 19, 2001Date of Patent: February 21, 2006Assignee: Bioimage A/SInventors: Sara Petersen Bjorn, Len Pagliaro, Ole Thastrup
-
Patent number: 6818443Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.Type: GrantFiled: June 1, 2001Date of Patent: November 16, 2004Assignee: BioImage A/SInventors: Ole Thastrup, Søren Tullin, Lars Kongsbak Poulsen, Sara Petersen Bjørn
-
Publication number: 20040018504Abstract: A method is described to assay for protein interactions in living cells, e.g. by the introduction of two heterologous conjugates into the cell. The method uses the measurement of cellular distribution of a detectable component (e.g. a GFP-labelled fluorescent probe) to indicate the presence or absence of an interaction between that component and a second component of interest. The method uses the knowledge that certain components can be stimulated to redistribute within the cell to defined locations. Inducible redistribution systems make it possible to determine if specific interactions occur between components. Inducible systems are described where it is demonstrated that the redistribution stimuli are essentially “null”, in that they affect no other system in the cell during the assay period, other than the component whose redistribution can be induced.Type: ApplicationFiled: March 14, 2003Publication date: January 29, 2004Inventors: Sara Petersen Bjorn, Ole Thastrup, Bernard Robert Terry, Grith Hagel, Soren Jensby Nielsen
-
Publication number: 20030187056Abstract: An alternative therapeutic approach for PDE4 inhibition is disclosed. PDE4 dislocators, will remove the PDE4 away from the native location in the cell and thereby increase the concentration of cAMP in this location. By dislocating the PDE4, and thereby not acting directly on the catalytic, among phosphodiesterase inhibitors, well conserved site, the compound will act e.g. at the binding domain of the PDE4, thereby providing isoform-specific ‘inhibitors’ of PDE4. The dislocation of PDE4s are visualised with fusions to GFP. The native location is induced by treatment with Rolipram.Type: ApplicationFiled: March 13, 2003Publication date: October 2, 2003Inventors: Bernard Robert Terry, Kurt Marshall Scudder, Sara Petersen Bjorn, Ole Thastrup, Dorthe Christensen Almholt, Morten Praestegaard
-
Patent number: 6566083Abstract: The present invention relates to a method of detecting biologically active substances affecting intracellular processes, an isolated DNA, a vector and a cell for use in the method. More specifically, the present invention provides a method for detecting a biologically active substance that affects intracellular processes mediated through a protein kinase or a second messenger, which comprises incubating a cell with a test substance and measuring any change caused by the test substance in the flourescence of (i) a wild-type or modified green flourescent protein (GFP) having a protein kinase recognition site, (ii) a modified GFP containing a second messenger binding domain, or (iii) a hybrid polypeptide having a wild-type or modified GFP and an attached protein kinase recognition site or a second messenger binding domain.Type: GrantFiled: July 2, 1999Date of Patent: May 20, 2003Assignee: Novo Nordisk A/SInventors: Ole Thastrup, Søren Tullin, Lars Kongsbak Poulsen, Sara Petersen Bjørn
-
Publication number: 20030082564Abstract: Cells are genetically modified to expresss a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence.Type: ApplicationFiled: February 5, 2002Publication date: May 1, 2003Applicant: BioImage A/SInventors: Ole Thastrup, Sara Petersen Bjorn, Soren Tullin, Kasper Almholt, Kurt Scudder
-
Patent number: 6518021Abstract: Cells are genetically modified to express a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Flourescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tryosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnkl, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signaling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of influence.Type: GrantFiled: October 7, 1999Date of Patent: February 11, 2003Assignee: BioImage A/SInventors: Ole Thastrup, Sara Petersen Bjørn, Soren Tullin, Kasper Almholt, Kurt Scudder
-
Publication number: 20020177189Abstract: A GFP with an F64L mutation and an E222G mutation is provided. This GFP has a bigger Stokes shift compared to other GFPs making it very suitable for high throughput screening due to a better resolution. This GFP also has an excitation maximum between the yellow GFP and the cyan GFP allowing for cleaner band separation when used together with those GFPs.Type: ApplicationFiled: June 19, 2001Publication date: November 28, 2002Inventors: Sara Petersen Bjorn, Len Pagliaro, Ole Thastrup
-
Publication number: 20020107362Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.Type: ApplicationFiled: June 1, 2001Publication date: August 8, 2002Applicant: BIOIMAGE A/SInventors: Ole Thastrup, Soren Tullin, Lars Kongsbak Poulsen, Sara Petersen Bjorn
-
Patent number: 6172188Abstract: The present invention relates to novel variants of the fluorescent protein GFP having improved fluorescence properties.Type: GrantFiled: March 17, 1997Date of Patent: January 9, 2001Inventors: Ole Thastrup, Søren Tullin, Lars Kongsbak Poulsen, Sara Petersen Bjørn